Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
The Effectiveness of Ketotifen (Mast Cell Inhibitor) as a Treatment for Insertional Achilles Tendinopathy
FY 2013-14
Summary
Achilles tendinopathy is a chronic injury that is characterized by pain and thickening in the Achilles tendon that leads to limitations in carrying out daily activities. Current Achilles tendinopathy therapies are not effective cures for the condition.
Recent research has identified a factor related to chronic tendon injury that warrants further investigation. Dr. Alex Scott demonstrated that people with Achilles tendinopathy have increased mast cells in their tendons. Mast cells are involved with tissue inflammation, and are prevalent in the tissues of people with inflammatory conditions such as asthma. The oral drug Ketotifen is a mast cell inhibitor, and is an effective treatment for other conditions where mast cells are involved. In another study, Dr. Scott found that inhibiting mast cells in mice with injured tendons improved tendon healing. Based on this evidence, this study proposes Ketotifen as a non-invasive treatment for Achilles tendinopathy in human subjects.
This study aims to assess the impact of Ketotifen as an oral drug treatment for chronic Achilles tendon pain by comparing two groups of participants with Achilles tendinopathy. For four weeks, one group will receive regular doses of Ketotifen, and the other group will receive a placebo. The groups will be compared on their levels of Achilles tendon pain during the treatment cycle, as well as secondary outcome measures such as functional limitation and morning stiffness. It is expected that pain and function will improve in the participants who received Ketotifen compared to those that received the placebo.
A second aim of this study is to prepare for a subsequent clinical trial. If Ketotifen is demonstrated in this study to be an effective treatment for Achilles tendinopathy, a larger-scale study can be carried out to determine the efficacy of Ketotifen alongside gold-standard treatment (exercise-based rehabilitation). Data from this study can also help inform the clinical trial by determining how many participants would be necessary to recruit.
Achilles tendinopathy causes a significant individual and societal impact, and no current therapies are sufficient cures. The success of this study would contribute to the understanding of Achilles tendinopathy, and provide a candidate for effective treatment of the condition.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
312019
Name
White Lynita D
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The Effectiveness of Ketotifen (Mast Cell Inhibitor) as a Treatment for Insertional Achilles Tendinopathy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Achilles Tendon; Ketotifen; Mast Cell; Pilot Study; Tendinopathy; Treatment
Abstract
Achilles tendinopathy is a chronic injury that is characterized by pain and thickening in the Achilles tendon that leads to limitations in carrying out daily activities. Current Achilles tendinopathy therapies are not effective cures for the condition.
Recent research has identified a factor related to chronic tendon injury that warrants further investigation. Dr. Alex Scott demonstrated that people with Achilles tendinopathy have increased mast cells in their tendons. Mast cells are involved with tissue inflammation, and are prevalent in the tissues of people with inflammatory conditions such as asthma. The oral drug Ketotifen is a mast cell inhibitor, and is an effective treatment for other conditions where mast cells are involved. In another study, Dr. Scott found that inhibiting mast cells in mice with injured tendons improved tendon healing. Based on this evidence, this study proposes Ketotifen as a non-invasive treatment for Achilles tendinopathy in human subjects.
This study aims to assess the impact of Ketotifen as an oral drug treatment for chronic Achilles tendon pain by comparing two groups of participants with Achilles tendinopathy. For four weeks, one group will receive regular doses of Ketotifen, and the other group will receive a placebo. The groups will be compared on their levels of Achilles tendon pain during the treatment cycle, as well as secondary outcome measures such as functional limitation and morning stiffness. It is expected that pain and function will improve in the participants who received Ketotifen compared to those that received the placebo.
A second aim of this study is to prepare for a subsequent clinical trial. If Ketotifen is demonstrated in this study to be an effective treatment for Achilles tendinopathy, a larger-scale study can be carried out to determine the efficacy of Ketotifen alongside gold-standard treatment (exercise-based rehabilitation). Data from this study can also help inform the clinical trial by determining how many participants would be necessary to recruit.
Achilles tendinopathy causes a significant individual and societal impact, and no current therapies are sufficient cures. The success of this study would contribute to the understanding of Achilles tendinopathy, and provide a candidate for effective treatment of the condition.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
White, Lynita D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~